<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775787</url>
  </required_header>
  <id_info>
    <org_study_id>ECIG 13-002-3</org_study_id>
    <nct_id>NCT01775787</nct_id>
  </id_info>
  <brief_title>Effects of Electronic Cigarettes on Nicotine Concentrations</brief_title>
  <acronym>ECIG</acronym>
  <official_title>Effects of Electronic Cigarettes on Nicotine Concentrations Before and 5, 10, 15, 20 and 30 Minutes After Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether nicotine levels increase with electronic cigarettes. It will
      also examine whether electronic cigarettes alter lung function tests. The study will obtain
      preliminary data on the medical effects of electronic cigarettes, with two different nicotine
      flavors, tobacco and tobacco with menthol, which are available for over the counter purchase.

      The electronic cigarettes and juice used in this study is available for purchase through the
      internet. An investigational new drug application (IND) is not needed for this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized two-period cross-over study in which subjects who smoke greater than 10
      cigarettes will be instructed to quit smoking and use either Joye (Ego C brand) with an 18 mg
      cartridge containing either a tobacco or tobacco mentholated flavor for one week. Prior to
      starting e-cig use we will collect one blood sample for nicotine/cotinine as a measure of
      overall nicotine exposure. Subjects will use the device for one week and at the end of
      approximately one week of use, we will assess nicotine/cotinine concentrations (before and 5,
      10, 15, 20 and 30 minutes after the onset of ECIG use), pulmonary function tests (before and
      5 minutes after ECIG use), and subjective impressions of satisfaction. At the end of one
      week, subjects will be crossed over to the other condition and assessments will be repeated
      after another week of E-cigarette use.

      A total of 30 smokers will be recruited from the surrounding areas via advertisements in
      newspapers and radio advertisements and University of Connecticut Health Center (UCHC)
      broadcast e-mail. Posters will be placed in clinical areas to recruit from physician
      practices. Current smokers are being proposed for three reasons: 1) we wish to determine
      whether nicotine levels from e-cigarettes rise to the levels of regular cigarettes when used
      by regular smokers; 2) we wish to determine if there are any differences seen in pulmonary
      function when a person switches from regular cigarettes to e-cigarettes; 3) we wish to
      evaluate the level of satisfaction that regular smokers have with e-cigarettes. All of these
      questions will have implications for later, more extensive studies of e-cigarettes,
      particularly in regard to their utility as a smoking cessation modality.

      Once a potential study subject calls and expresses interest in the study, preliminary
      inclusion criteria will be assessed over the phone. Inclusion criteria include 1) at least 18
      years of age; 2) current use of at least 10 cigarettes daily; 3) willing to abstain from
      cigarette smoking, and substitute e-cigs, for approximately 2 weeks; 4) able to read and sign
      a consent form; Exclusion criteria: 1) unstable medical or psychiatric disorders as
      determined by the principal investigator; 2) pregnancy; 3) known hypersensitivity to nicotine
      or propylene glycol or menthol; 4) previous myocardial infarction (M.I.) or stroke; 5)
      uncontrolled hypertension [Blood pressure (BP) &gt;160/100); 6) insulin dependent diabetes; 7)
      known chronic obstructive pulmonary disease (COPD) or asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use</measure>
    <time_frame>7-10 days</time_frame>
    <description>To determine the effects of acute E-cig use on venous nicotine concentrations 5 minutes before and 5 minutes after 7-10 days of e-cigarette use.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Health Behavior</condition>
  <arm_group>
    <arm_group_label>Tobacco Flavor/ Tobacco &amp; Menthol Flavor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.
Nicotine with Tobacco Flavor and Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobacco &amp; Menthol Flavor/Tobacco Flavor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.
Nicotine with Tobacco Flavor and Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine with Tobacco Flavor and Tobacco &amp; Menthol Flavor</intervention_name>
    <description>Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco &amp; Menthol Flavor for 7-10 days or Tobacco &amp; Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days</description>
    <arm_group_label>Tobacco Flavor/ Tobacco &amp; Menthol Flavor</arm_group_label>
    <arm_group_label>Tobacco &amp; Menthol Flavor/Tobacco Flavor</arm_group_label>
    <other_name>Tobacco Flavor</other_name>
    <other_name>Tobacco &amp; Menthol Flavor</other_name>
    <other_name>Electronic Cigarette</other_name>
    <other_name>Nicotine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoking 10 cigarettes daily

          -  Agree to abstain from smoking and use electronic cigarettes for 2 weeks

        Exclusion Criteria:

          -  Unstable medical or psychiatric disorders as determined by the principal investigator

          -  Pregnancy

          -  Known hypersensitivity to nicotine or propylene glycol or menthol

          -  Recent M. I. or stroke

          -  Uncontrolled hypertension (BP.&gt;160/100)

          -  Insulin dependent diabetes

          -  Known COPD or asthma

          -  Alcohol or other drug abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl Oncken, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-3940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/25762758</url>
    <description>Nicotine concentrations with electronic cigarette use: effects of sex and flavor</description>
  </link>
  <results_reference>
    <citation>Oncken CA, Litt MD, McLaughlin LD, Burki NA. Nicotine concentrations with electronic cigarette use: effects of sex and flavor. Nicotine Tob Res. 2015 Apr;17(4):473-8. doi: 10.1093/ntr/ntu232.</citation>
    <PMID>25762758</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <results_first_submitted>November 18, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Cheryl Oncken</investigator_full_name>
    <investigator_title>Professor, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tobacco Flavor/ Tobacco &amp; Menthol Flavor</title>
          <description>Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.
Nicotine with Tobacco Flavor or Tobacco &amp; Menthol Flavor (18mg/mL nicotine</description>
        </group>
        <group group_id="P2">
          <title>Tobacco &amp; Menthol Flavor/Tobacco Flavor</title>
          <description>Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.
Nicotine with Tobacco Flavor or Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First 7-10 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>family emergency</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>time commitment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>concerns with using IV</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second 7-10 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>time commitment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>concerns with using IV</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis Nicotine Concentrations before ad 5 minutes after Ecig use, regardless of flavor.</population>
      <group_list>
        <group group_id="B1">
          <title>Nicotine With Tobacco Flavor and With Tobacco &amp; Menthol Flavor</title>
          <description>Smokers were assigned to electronic cigarettes containing 18mg/mL of nicotine in either a tobacco flavor solution or a tobacco and menthol flavor solution and then switched to other flavor for an additional 7 to 10 days. Monitoring sessions occurred on the last day of trial period of each flavor.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use</title>
        <description>To determine the effects of acute E-cig use on venous nicotine concentrations 5 minutes before and 5 minutes after 7-10 days of e-cigarette use.</description>
        <time_frame>7-10 days</time_frame>
        <population>Nicotine Concentrations Before and 5 Minutes After Ecig Use were intended to be analyzed, regardless of flavor, as pre-specified in the study protocol,</population>
        <group_list>
          <group group_id="O1">
            <title>Tobacco Flavor</title>
            <description>Subjects received tobacco flavored nicotine for 7-10 days</description>
          </group>
          <group group_id="O2">
            <title>Tobacco &amp; Menthol Flavor</title>
            <description>Subjects received tobacco &amp; menthol flavored nicotine for 7-10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use</title>
          <description>To determine the effects of acute E-cig use on venous nicotine concentrations 5 minutes before and 5 minutes after 7-10 days of e-cigarette use.</description>
          <population>Nicotine Concentrations Before and 5 Minutes After Ecig Use were intended to be analyzed, regardless of flavor, as pre-specified in the study protocol,</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Ecig used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread=".66"/>
                    <measurement group_id="O2" value="4.11" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes after ecig use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread=".08"/>
                    <measurement group_id="O2" value="8.77" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period from Randomization to close of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tobacco Flavor &amp; Tobacco &amp; Menthol Flavor (TOB Flavor)</title>
          <description>AE occurred in intervention &quot;Tobacco Flavor Session 17-10 days&quot;
Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.
Nicotine with Tobacco Flavor or Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
        </group>
        <group group_id="E2">
          <title>Tobacco Flavor &amp; Tobacco &amp; Menthol Flavor (TOB/MENTH Flavor)</title>
          <description>AE occurred in intervention &quot;Tobacco Flavor Session 27-10 days&quot;
Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.
Nicotine with Tobacco Flavor or Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
        </group>
        <group group_id="E3">
          <title>Tobacco &amp; Menthol Flavor &amp; Tobacco Flavor (TOB/MENTH Flavor)</title>
          <description>AE occurred in intervention &quot;Tobacco &amp; Menthol Flavor Session 17-10 days&quot;
Subjects randomized to Tobacco &amp; Menthol Flavor group 7-10 days, then crossed over to Tobacco Flavor for 7-10 days.
Nicotine with Tobacco Flavor or Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
        </group>
        <group group_id="E4">
          <title>Tobacco &amp; Menthol Flavor &amp; Tobacco Flavor (TOB Flavor)</title>
          <description>AE occurred in intervention &quot;Tobacco Flavor Session 2 7-10 days&quot;
Subjects randomized to Tobacco &amp; Menthol Flavor group 7-10 days, then crossed over to Tobacco Flavor for 7-10 days.
Nicotine with Tobacco Flavor or Tobacco &amp; Menthol Flavor (18mg/mL nicotine)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thoat itchy and cough</sub_title>
                <description>HEENT ( head, ears, eyes, nose and throat)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Concerns with using IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Time Commitment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Family Emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cheryl Oncken</name_or_title>
      <organization>UConn Health</organization>
      <phone>860-679-3425</phone>
      <email>oncken@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

